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Abstract
Objective: Tau hyperphosphorylation at threonine 217 (pT217) in cere-
brospinal fluid (CSF) has recently been linked to early amyloidosis and could
serve as a highly sensitive biomarker for Alzheimer’s disease (AD). However, it
remains unclear whether other tauopathies induce pT217 modifications. To
determine if pT217 modification is specific to AD, CSF pT217 was measured in
AD and other tauopathies. Methods: Using immunoprecipitation and mass
spectrometry methods, we compared CSF T217 phosphorylation occupancy
(pT217/T217) and amyloid-beta (Ab) 42/40 ratio in cognitively normal individ-
uals and those with symptomatic AD, progressive supranuclear palsy, corti-
cobasal syndrome, and sporadic and familial frontotemporal dementia. Results:
Individuals with AD had high CSF pT217/T217 and low Ab42/40. In contrast,
cognitively normal individuals and the majority of those with 4R tauopathies
had low CSF pT217/T217 and normal Ab 42/40. We identified a subgroup of
individuals with increased CSF pT217/T217 and normal Ab 42/40 ratio, most
of whom were MAPT R406W mutation carriers. Diagnostic accuracies of CSF
Ab 42/40 and CSF pT217/T217, alone and in combination were compared. We
show that CSF pT217/T217 9 CSF Ab 42/40 is a sensitive composite biomarker
that can separate MAPT R406W carriers from cognitively normal individuals
and those with other tauopathies. Interpretation: MAPT R406W is a tau muta-
tion that leads to 3R+4R tauopathy similar to AD, but without amyloid neu-
ropathology. These findings suggest that change in CSF pT217/T217 ratio is not
specific to AD and might reflect common downstream tau pathophysiology
common to 3R+4R tauopathies.
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Introduction
Alzheimer’s disease (AD) is characterized by the plaque
deposition of amyloid-beta 42 peptide (Ab 42) and aggre-
gation of hyperphosphorylated tau in neurofibrillary tan-
gles, neuritic plaques, and neuropil threads in the brain.
Concomitant decrease in Ab 42/40 ratio and increase of
phosphorylated tau (ptau) species in the cerebrospinal
fluid (CSF) have been used as biomarkers for AD amyloi-
dosis and as surrogates of AD tau neuropathology,
respectively.1,2 Increasing evidence suggests that either
CSF tau phosphorylation at threonine 217 measured as
absolute concentration (pT217) or as phosphorylation
occupancy (pT217/T217) is a specific and more sensitive
biomarker for AD, outperforming the well-established
measure of CSF ptau level at threonine 181 (pT181).3–8
CSF pT181 level increase is strongly associated with the
increase in total CSF tau concentration and is assumed to
reflect tau neuropathology. However, CSF pT217 and
pT217/T217 more strongly correlate with amyloid neu-
ropathology measured by amyloid Pittsburgh compound
B (PiB)-positron emission tomography (PET) imaging
than total CSF tau.3,9,10 Moreover, pT217 can predict the
beginning of AD clinical symptoms in families with AD
mutations better than pT181.3 Thus, it remains unclear if
hyperphosphorylation at T217 is an early and direct con-
sequence of amyloidosis or whether it is a downstream
marker of tau pathology. In this context, it is also unclear
if CSF pT217/T217 changes in primary tauopathies in the
absence of amyloid pathology.
Other neurodegenerative dementing illnesses associated
with tau neuropathology, including progressive supranu-
clear palsy (PSP), corticobasal syndrome (CBS), and
behavioral variant frontotemporal dementia (bvFTD),
currently have no CSF or imaging biomarkers. Diagnosis
primarily depends on clinical assessment, which may be
confirmed after brain autopsy. The lack of reliable in vivo
biomarkers challenges accurate clinical diagnoses, with
implications for the design and implementation of clinical
trials.11–13 Previous studies, mostly measuring absolute
CSF pT181 concentrations using immunoassays, suggested
that increases in pT181 are specific to AD.14–18 However,
global change in CSF tau isoforms concentration may
contribute to pT181 absolute concentration without rela-
tive change in pT181 phosphorylation.19,20 pT181 phos-
phorylation occupancy measured as pT181/T181 ratio is
essential to fully interpret the changes in CSF pT181. Fur-
thermore, some recent studies using immunoassays and
mass spectrometry (MS) showed that an increase in CSF
pT217 concentration is specific to AD and not observed
in other neurodegenerative diseases.3,4,7,8 However, previ-
ous studies often do not take into account amyloid co-
neuropathology that frequently increases with age and in
many neurodegenerative diseases.
In order to evaluate the effect of tau phosphorylation
in non-AD tauopathies, including PSP, CBS, and bvFTD,
we measured CSF ptau and CSF Ab using sequential
immunoprecipitation (IP) and MS. CSF pT217/T217 and
pT181/T181 ratios were calculated to differentiate tau
phosphorylation changes from CSF total tau variation.
CSF Ab 42/40 ratio was calculated within the same partic-
ipant and used as a surrogate for amyloid neuropathol-
ogy. A cohort of cognitively normal age-matched controls
(AMC) and individuals with symptomatic AD, PSP, CBS,
and sporadic and familial FTD were analyzed. We
assessed the correlation between CSF ptau and CSF Ab
42/40 ratios in each disease group and evaluated diagnos-
tic relevance of CSF ptau alone and in combination with
CSF Ab 42/40 to assess their ability to discriminate indi-




All studies were approved by the Institutional Review
Board at Washington University in St. Louis, MO, USA
and the Ethics Committee of the Montpellier University
Hospital (CSF-NeuroBANK #DC-2008-417 at the certified
NFS 96-900 CHU resource center BB-0033-00031 [http://
www.biobanques.eu]). All participants or their delegates
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consented to the collection and sharing of biofluid sam-
ples. Exclusion criteria included contradiction to lumbar
punctures (LPs) or lumbar catheters including a bleeding
disorder, active anticoagulation, and active infection.
Authorization to handle personal data was granted by the
French Data Protection Authority (CNIL) under the
number 1709743 v0.
AMC and individuals with mild AD were recruited at
the Knight Alzheimer Disease Research Center (ADRC) at
Washington University School of Medicine as part of
Stable Isotope Labeling Kinetics (SILK) studies. AMC are
volunteers who were enrolled for research purposes and
are cognitively normal. This included two distinct cohorts
of symptomatic participants (WashU-A, and WashU-B).
Individuals from the WashU-A cohort participated in
36hr lumbar catheter studies.21 Individuals from the
WashU-B cohort participated in the SILK study that
involved five LPs over 4 months.22 Individuals were diag-
nosed by clinical assessment and classified according to
the Clinical Dementia Rating (CDR).23 In addition to
interviews of patient and collateral source, brain PET
imaging data and diagnostic CSF results were reviewed if
available. This cohort includes clinical AD patients who
did not have biomarkers consistent with AD, who were
classified as non-AD dementia. WashU-A cohort was fur-
ther classified with Amyloid PET positivity based on PiB
imaging. Young normal controls (YNC) between the ages
of 18–64 without currently diagnosed neurological disor-
ders, were referred from Volunteers for Health at Wash-
ington University. Brain tumor patients were referred
from Barnes Jewish Hospital. Patients with PSP, CBS, and
sporadic bvFTD were referred from affiliated Memory
Diagnostic Center and Movement Disorders Clinics.
MAPT P301L and R406W mutation carriers were clini-
cally assessed locally at Washington University and
referred from the Longitudinal Evaluation of Familial
Frontotemporal Dementia Study (LEFFTDS; https://
www.allftd.org/artfl-lefftds; Site PI NG). Eight participants
(1 PSP, 3 MAPT R406W, 2 CBS, and 2 AMC) had
repeated LPs and CSF collection.
Montpellier participants were referred from the Mem-
ory Resources and Research Center of Montpellier. They
were categorized into AD, CBS, PSP, bvFTD, and CBS-
PSP continuum based on clinical, neuropsychological,
brain imaging, and follow-up assessments. CSF biomark-
ers of Ab42, tau, pT181 concentrations were also mea-
sured with Enzyme-Linked immunosorbent Assay
(ELISA) and Ab42/40 ratio was calculated.24 AD was
diagnosed according to accepted criteria25,26 and based on
the ATN classification27; all AD participants had at least
two abnormal CSF biomarkers. This includes AD focal
phenotype which refers to predominant language, behav-
ioral, visuospatial, apraxia phenotype with CSF
biomarkers of AD. Some PPA endophenotype AD cases
were included in the AD focal phenotype (n = 5). CBS
and PSP were diagnosed according to international crite-
ria.28 bvFTD may be attributed to frontotemporal lobar
degeneration (FTLD)-tau, FTLD-TDP, and FTLD-
FUS.29,30 Some language endophenotype FTLD were
included in bvFTD (n = 3). The CBS PSP continuum
included patients with CBS clinical phenotypes that
evolved into PSP during follow-up.31
CSF collection
CSF from individuals with AD and AMC in the WashU-
A cohort were collected via a catheter as previously
described.21 CSF from AMC and individuals with symp-
tomatic AD, PSP, CBS, and bvFTD in the WashU-B
cohort were obtained via LP with gravity collection and
centrifugation as previously described.22 CSF from MAPT
mutation families was collected according to the stan-
dardized protocol at the Biomarker Core at the Washing-
ton University School of Medicine.32 CSF from
individuals with brain tumors was obtained via lumbar
drain using a catheter before or after surgery.
CSF from the Montpellier cohort was collected using
the standardized protocol for the collection, centrifuga-
tion, and storage at Memory Resources and Research
Center of Montpellier.33–35 Briefly, the atraumatic needle
was used for LP, with CSF collected into 10 mL
polypropylene tube (ref 62.610.201, Sarstedt, Germany)
and protein low binding Eppendorf tubes (LoBind
microtubes Eppendorf, ref 022431064, Hamburg, Ger-
many). CSF was not centrifuged before aliquoting and
storage at 80°C. CSF tau and pT181 concentrations
were measured using the standardized commercially avail-
able INNOTEST sandwich ELISA X-MAP following
Fujirebio instructions. CSF Ab 42 and Ab 40 were mea-
sured using INNOTEST sandwich ELISA from Fujirebio.
Sequential IP and MS methods for CSF Ab
and Tau
CSF Ab was analyzed as previously described36 with the
following modifications. Master mix containing detergent
and chaotropic reagents (final 1% NP-40, 5 mmol/L
guanidine, protease inhibitor cocktail) and internal stan-
dards for tau (15N labeled 2N4R recombinant tau) and
Ab (15N labeled synthetic Ab 40, and 42) were prepared
in low-binding Axygen tubes (Fisher Scientific, Pittsburgh,
PA, USA, MCT-175). 500–1000 µL of CSF was added and
immunoprecipitated with the HJ5.1 mid-domain Ab anti-
body. After washing, samples were digested with LysN
protease, desalted, and analyzed by Xevo TQ-S mass spec-
trometer (Waters Corporation, Milford, MA, USA).
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CSF tau and ptau were analyzed as previously
described9,22 with the following modifications. Post-HJ5.1
immunoprecipitated CSF samples containing tau internal
standards were sequentially immunoprecipitated with
Tau1 mid-domain and HJ8.5 N-terminus tau antibodies.
After washing, samples were digested with trypsin,
desalted, and analyzed on Orbitrap Fusion mass spec-
trometer (Thermo Fisher Scientific, San Jose, CA, USA).
MS method measuring pT217 and pT181 was described
previously.3
Amyloid and Tau PET imaging
Amyloid PiB-PET, AV45-PET, and Tau AV1451-PET
imaging measurements were performed in a subset of AD
and AMC participants from the Knight ADRC at Wash-
ington University School of Medicine. Data were collected
and processed as previously described.22
Statistics
Receiver operating characteristic (ROC) and one-way
ANOVA analyses were performed using GraphPad Prism
software (GraphPad, San Diego, CA, USA, v8.3.0.). After
confirming the normal distribution of the data, one-way
ANOVA followed by post hoc analyses (Tukey test) were
performed. Data were represented as mean  SEM.
Results
Participants and study workflow
Participants’ demographics and clinical characteristics are
summarized in Table 1. For the purpose of the analyses,
study cohorts were divided into several groups. The “AD”
group (n = 80) included patients with amnestic-
predominant clinically “typical” AD (n = 66) and those
with focal variants (n = 14). bvFTD MAPT R406W muta-
tion carriers (n = 5) were grouped as “R406W.” All neu-
rodegenerative diseases other than AD, and MAPT
R406W mutation carriers were grouped as “4R tauopa-
thy” (n = 74). This group included individuals with PSP
(n = 16), CBS (n = 15), CBS-PSP continuum (n = 7),
sporadic bvFTD (n = 28), and bvFTD MAPT P301L
mutation carriers (n = 3), which were primarily 4R tauo-
pathies with 4R tau as primary isoform in the brain
aggregates. Note that sporadic bvFTD was listed under
“4R tauopathy” group; however, they were pathologically
unconfirmed and might contain FTLD-tau, FTLD-TDP43,
FTLD-FUS, and small number of 3R tauopathy such as
Pick’s disease. One of these participants was later found
to have C9orf72 mutation. Cognitively normal controls
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n = 64), YNC (n = 26), and brain tumor patients (n = 8)
who were cognitively normal.
Individuals in YNC (42.3  2.4), Brain tumor
(50.2  2.6), and MAPT P301L (37.2  3.6) groups were
younger than AMC (73.0  0.8) and participants with
neurodegenerative diseases including AD (73.3  0.9),
CBS (68.6  2.6), CBS PSP continuum (70.7  1.4), PSP
(71.0  2.6), and sporadic bvFTD (62.1  1.3) (Table 1,
Fig. S1).
All 252 CSF baseline samples and 8 CSF follow-up
samples were measured with sequential IP/MS methods
for CSF Ab 42, Ab 40, pT217, T217, pT181, and T181
concentrations. CSF Ab 42/40, pT217/T217, pT181/T181
ratios were calculated. The workflow used to categorize
the different clinical groups is described in Figure S2.
Determining cutoffs for IP/MS CSF Ab 42/40
and CSF pT217/T217
To define amyloid positivity cutoff for CSF Ab 42/40
measured by IP/MS, we used amyloid PiB-PET results
from 48 participants in the WashU-A cohort (cutoff 0.18;
Figure 1. MAPT R406W carriers have increased CSF pT217/T217 without Amyloid pathology. (A) All samples (n = 252) were plotted to quadrant
analyses using the cutoffs calculated in the WashU-A cohort (CSF Ab 42/40 cutoff = 0.086, CSF pT217/T217 cutoff = 4.76). (B–E) Pie charts
showing the number of participants in each clinically classified group for each quadrant: II (B), I (C), III (D), and IV (E). CSF, cerebrospinal fluid.
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Fig. S2A, Table 1).21 CSF Ab 42/40 was significantly
decreased in the amyloid-PiB+ cohort (Fig. S3A). A ROC
curve analysis was performed and a Youden’s index value
of 0.086 was selected as a cutoff for CSF Ab 42/40 to
maximize discrimination between cohorts (area under the
curve [AUC] = 0.921, p < 0.0001; Fig. S3B).
To determine ptau abnormality cutoff for CSF pT217/
T217, we used CSF Ab 42/40 values in amyloid-PiB+
patients from the WashU-A cohort (Fig. S2A). We added
another subset of 37 participants with only MS CSF Ab
42/40 measurements. CSF pT217/T217 was significantly
increased in amyloid+ individuals based on PiB-PET and
CSF Ab 42/40 measurements (Fig. S3C). A ROC curve
analysis was performed and a Youden’s index value of
4.76 was calculated as a cutoff for CSF pT217/T217
(AUC = 0.983, p < 0.0001; Fig. S3D).
The same ROC analyses were performed for concentra-
tions of CSF pT217, pT181, total tau, and phosphoryla-
tion occupancy at T181 (pT181/T181. Fig. S3E–L). AUC
for each of these biomarkers was 0.949 (pT217), 0.816
(pT181), 0.698 (total tau), and 0.934 (pT181/T181),
respectively, supporting the previous finding that CSF
pT217/T217 is a superior discriminative AD biomarker.3,9
Association between IP/MS CSF Ab 42/40 and
CSF pT217/T217
To evaluate the relationship between IP/MS CSF Ab 42/
40 and pT217/T217, we plotted both ratios for each of
the 255 participants. Based on the calculated 0.086 and
4.8 cutoffs for CSF Ab 42/40 and CSF pT217/T217,
respectively, we defined quadrants as follows: I (amy-
loid, ptau+), II (amyloid+, ptau+), III (amyloid+,
ptau), and IV (amyloid, ptau) (Fig. 1A–E, Fig. S3B).
In quadrant II (amyloid+, ptau+), 88% (73/83) of indi-
viduals were clinically identified as AD (Fig. 1B). Overall,
91% (73/80) of individuals with AD were plotted in II
(Fig. S4A). Seven participants clinically identified as AD
were divided into quadrant I (n = 3), III (n = 1), and IV
(n = 3, Fig. 1B–D). A subset of Controls (AMC [n = 5],
CBS [n = 2], PSP [n = 2] and bvFTD [n = 1]) were also
assigned to quadrant II (Fig. 1A and B).
Eighty four percent (82/98) of controls were plotted in
IV and 55% (82/150) of individuals in IV were controls
(Fig. 1E, Fig. S4B). Eighty percent (12/15) of CBS and
81% (13/16) of PSP were also in IV (Fig. S4C and D) as
well as 71% (5/7) of the CBS PSP continuum.
CSF Ab 42/40 and CSF pT217/T217 were negatively asso-
ciated and displayed an L-shaped curve (Fig. 1). To better
understand the dynamic association between CSF Ab 42/40
and CSF pT217/T217 profile in the context of AD contin-
uum, we assessed amyloid burden measured with PiB-PET
and AV45-PET imaging and tau aggregation by AV1451-
PET imaging in a subset of participants (Fig. S5). Ab aggre-
gation measured by both PET tracers gradually and signifi-
cantly increased from quadrant IV, III to II (Fig. S5A and B).
All the Controls in quadrant III were AMC (Fig. 1A) and




















#1 IV No dementia 40 M 0.142 3.69 0.524 26.0
IV No dementia 41 0.152 3.75 0.572 24.6
#2 I No dementia 40 M 0.130 5.28 0.688 40.6
#3 I No dementia 52 F 0.127 5.30 0.671 41.9
I No dementia 55 0.132 5.86 0.774 44.4
#4 I Symptomatic 64 F 0.121 5.47 0.659 45.4
#5 IV Asymptomatic,
other primary
69 F 0.108 4.73 0.513 43.7








4 I, 1 IV No dementia,
Symptomatic,
other primary
63.0  4.1 - 0.118  0.0056 5.3  0.19 0.628  0.049 45.2  1.5
Average
all
– – 54.5  4.8 - 0.127  0.0059 4.9  0.28 0.615  0.049 39.6  3.3
CSF, cerebrospinal fluid.
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none belonged to the YNC (age <64). However, within
AMC, there was no significant difference in age in quadrant
III (74.8  2.4) and quadrant IV (72.4  0.6). These suggest
that individuals in quadrant III with amyloid positivity may
be defined as presymptomatic AD without abnormal tau
phosphorylation.27 In contrast, tau aggregation measured by
AV1451-PET only increased in quadrant II (Fig. S5C), sup-
porting CSF Ab 42/40 and amyloid PET change before CSF
pT217/T217 and tau PET. Importantly, a significant negative
correlation between CSF Ab 42/40 and CSF pT217/T217 was
observed in quadrants III and IV (ptau-) including most
controls, PSP, CBS, and bvFTD (Fig. S6).
MAPT R406W carriers have increased pT217/
T217 ratio without amyloid pathology
Quadrant I (amyloid, ptau+) was populated by individ-
uals with bvFTD, PSP, AD, or CBS (Fig. 1C). Interest-
ingly, 45% (5/11) were bvFTD, and all but one (80%, 4/
5) were MAPT R406W mutation carriers (Fig. S4F,
Table 2). All (5/5) MAPT R406W mutation carriers ana-
lyzed in this study were amyloid negative (quadrant I and
IV), supporting the absence of amyloid neuropathology
in MAPT R406W carriers (Table 2). Only one out of five
MAPT R406W mutation carriers who were in their 40s
and asymptomatic throughout the study was CSF pT217/
T217 negative (quadrant IV) at both baseline and follow-
up visit; all other MAPT R406W mutation carriers were
CSF pT217/T217 positive (quadrant I) regardless of their
pre/symptomatic status. One participant (#5) who was
asymptomatic at baseline and developed dementia in
follow-up visit 4 years later had CSF pT217/T217 just
below the threshold at baseline (quadrant IV), but CSF
pT217/T217 increased in the follow-up (quadrant I), sug-
gesting that the longitudinal changes in this biomarker
could reflect disease progression. In comparison, five
other participants with follow-up visits within 1 year (1
PSP in quadrant I, 2 CBS, and 2 AMC in quadrant IV)
remained in the same quadrant between baseline and
follow-up (Table S1). These results suggest that increasing
age and emergence of symptoms associate with increases
in CSF pT217/T217 in MAPT R406W mutation carriers.
Diagnostic values of IP/MS CSF Ab 42/40,
pT217/T217, and composite biomarkers in
AD and MAPT R406W mutation carriers
Next, we compared the diagnostic performance of IP/MS
CSF Ab 42/40 and CSF pT217/T217, with composite
biomarkers consisting of pT217/T217 multiplied by CSF
Ab 42/40 and CSF pT217/T217 divided by Ab 42/40
(Fig. 2, Table 3, Fig. S7). For this analysis, the four clini-
cal groups previously defined ("AD,” “R406W,” “4R
tauopathy,” and “Control”) were compared. CSF Ab 42/
40 ratio and CSF pT217/T217 used alone only separate
AD from the other three groups (Fig. 2A and B). How-
ever, the R406W group had significantly increased CSF
Ab 42/40 9 pT217/T217 composite biomarker compared
to what was observed in the Control and 4R tauopathy
groups (Fig. 2C). This composite biomarker demon-
strated excellent ability to separate the R406W group
from the 4R tauopathy (AUC = 0.948) and Control
groups (AUC = 0.961). When this composite biomarker
was used, 100% of MAPT R406W mutation carriers were
above the cutoff of 0.50 for R406W versus control
(Table 3). CSF pT217/T217 divided by CSF Ab 42/40 per-
formed similarly to CSF Ab 42/40 and CSF pT2117/T217
alone, and could not distinguish R406W from other
groups (Fig. 2D, Table 3).
IP/MS CSF total tau and ptau concentrations
are not efficient biomarkers for MAPT
R406W carriers
Neither CSF pT217, pT181, total tau, nor phosphoryla-
tion occupancy at T181 (pT181/T181) were as efficient as
the composite biomarker CSF pT217/T217 9 CSF Ab 42/
40 at separating MAPT R406W mutation carriers from
individuals with other neurodegenerative dementing ill-
nesses (Figs. S8, S9). CSF pT181/T181 was significantly
decreased in sporadic bvFTD (including FTLD-tau,
FTLD-TDP43, and FTLD-FUS) compared to AD, AMC,
and MAPT R406W mutation carriers (Figs. S8D, S9D).
When regrouped, CSF pT181/T181 was able to separate
sporadic bvFTD group from AD (AUC = 0.959), Control
(AUC = 0.752), and other tauopathies including CBS,
PSP, and FTD-MAPT including R406W and P301L
(AUC = 0.707. Fig. S10). However, the specificity and
sensitivity of CSF pT181/T181 to separate sporadic bvFTD
from other tauopathies and control were not as high as
that of CSF pT217/T217 in identifying MAPT R406W
mutation carriers.
Discussion
MAPT R406W mutation carriers have
increased pT217/T217 without amyloid
pathology
CSF pT217/T217 strongly correlates with amyloid
pathology measured by amyloid PET in AD,9 but it
was unproven whether pT217/T217 was a readout for
CSF amyloid pathology or tau pathology. In this study,
we first showed a specific correlation between CSF Ab
42/40 and CSF pT217/T217 in individuals with symp-
tomatic AD. Even in presymptomatic AD, CSF Ab 42/
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40 and CSF pT217/T217 correlate when slight changes
in phosphorylation are observed, consistent with previ-
ous reports showing a correlation between PiB-PET and
CSF pT217/T217.3,9 Neither CSF Ab 42/40 nor CSF
pT217/T217 were altered in other tauopathies, including
PSP, CBS, and most sporadic and familial FTD. How-
ever, we found that MAPT R406W mutation carriers
have increased CSF pT217/T217 independent of amyloid
pathology, demonstrating that increased CSF pT217/
T217 is, indeed, a biomarker of pathological tau modi-
fication common to AD and MAPT R406W associated
dementia and that amyloid pathology is not a prerequi-
site to this modification. This suggests that there is a
common tau pathology downstream of AD and MAPT
Figure 2. CSF Ab 42/40, CSF pT217/T217, and composite biomarkers for diagnosis of AD, and MAPT R406W mutation carriers. (A) CSF Ab 42/
40 is significantly decreased in AD (ANOVA, p < 0.0001). (B) CSF pT217/T217 is significantly increased in AD (ANOVA, p < 0.0001). (C) CSF
pT217/T217 9 CSF Ab 42/40 is significantly increased in AD compared to Control and 4R tauopathy group consisting mostly of 4R tauopathy
(PSP, CBS, FTD-MAPT P301L) and a subset of sporadic bvFTD (may contain FTD-TDP, FTD-FUS and 3R tauopathy. ANOVA, p < 0.0001). This is
also significantly increased in MAPT R406W carriers compared to control (ANOVA, p < 0.0001) and 4R tauopathy group (ANOVA, p = 0.0001).
(D) CSF pT217/T217 divided by CSF Ab 42/40, is significantly increased in AD (ANOVA, p < 0.0001). CSF, cerebrospinal fluid; AD, Alzheimer’s
disease; PSP, progressive supranuclear palsy; CBS, corticobasal syndrome; bvFTD, behavioral variant frontotemporal dementia.
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R406W mutation carriers, which results in specific tau
phosphorylation changes in the brain, leading to an
increase in CSF pT217/T217. Alternatively, two distinct
upstream mechanisms, one involving amyloid deposition
and the second involving MAPT R406W mutation,
could lead to the activation of a similar pathway,
Table 3. Diagnostic accuracy of combinations of CSF Ab 42/40 and CSF pT217T217 biomarkers for AD and FTD-MAPT R406W.
Test Diagnostic groups
n per









0.0004 100.0 96.3 >0.0985




<0.0001 94.2 90.0 >0.0768




<0.0001 91.3 87.8 <0.0798


















0.3459 56.5 55.1 >0.1231




<0.0001 96.3 92.9 >4.325




<0.0001 88.4 96.3 <4.338




0.0021 100.0 76.5 >3.678


















0.5895 65.2 45.9 <3.037











0.0009 92.8 100.0 <0.522




<0.0001 66.3 90.8 >0.448




<0.0001 85.5 68.8 <0.436











0.6375 73.9 36.7 >0.332
CSF pT217/T217 divided by CSFAb
42/40




0.0005 100.0 95.0 <61.1




<0.0001 92.8 95.0 <67.6











0.0184 85.5 80.0 <38.0











0.4746 14.5 94.9 <17.0
CSF, cerebrospinal fluid; AD, Alzheimer’s disease; AUC, area under the curve; FTD, frontotemporal dementia.
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ultimately leading to tau hyperphosphorylation and
aggregation.
MAPT R406W mutation’s similarity to AD
MAPT R406W mutation-related pathology shares multiple
clinical and neuropathological similarities with AD.
Unlike other MAPT mutation carriers, MAPT R406W
mutation carriers have later ages-at-symptomatic onset,
with clinical symptoms including memory loss emerging,
on average, in the mid-50s with slow progression.37 Most
pathological MAPT mutations such as P301L are located
in or around exon 10 and typically lead to 4R tau isoform
aggregation, resulting in 4R tauopathies. In contrast, the
MAPT mutations such as R406W and V337M are located
in the C-terminus of the tau protein in a domain com-
mon to both 3R and 4R tau isoforms, resulting in 3R+4R
mixed brain pathologies.38,39 The MAPT R406W muta-
tion, like AD, can thus be categorized as a 3R+4R tauopa-
thy and is differentiated from other 4R (CBS, PSP,
bvFTD related to MAPT mutations located on exon 10)
or 3R (Pick’s disease) tauopathies.
Filament structures in tau aggregates have been
recently resolved by cryo-electron microscopy for differ-
ent tauopathies such as AD and chronic traumatic
encephalopathy (CTE) (3R+4R), CBS (4R), and Pick’s
disease (3R).40–44 Consistent with neuropathological
findings, tau domains shared by 3R and 4R isoforms are
involved in AD and CTE tau aggregates, while 4R and
3R specific domains are, respectively, involved in corti-
cobasal degeneration and Pick’s disease aggregates.
Though no such structural data is available for MAPT
R406W, AD, MAPT R406W, and V337M have paired
helical filament structures,37,45 and AD Tau PET tracers
such as AV1451 bind to some extent in presymptomatic
MAPT R406W and V337M mutation carriers but not in
other tauopathies,45–49 suggesting that tau aggregates in
these 3R+4R tauopathies have similar characteristics.
However, how hyperphosphorylation at T217 contributes
to or associates with paired helical filament formation
remains to be addressed. Previous studies suggest that
CSF T217 is hyperphosphorylated in the early presymp-
tomatic stages of AD, and is detectable more than
20 years before the emergence of clinical symptoms,
while tau aggregates detected by PET imaging increase
near symptom onset.9 We speculate that in 3R+4R tauo-
pathies including MAPT R406W mutation carriers, (1)
CSF pT217/T217 becomes abnormal prior to symptom
onset when tau paired helical filament formation begins
but it is below the detection limit by tau PET imaging
followed by evident changes in Tau PET imaging; or,
(2) CSF T217 hyperphosphorylation is not directly asso-
ciated with the formation of neurofibrillary tangles but
reflects an abnormal cellular metabolism affecting tau
and leading ultimately to tau aggregation.
Composite biomarker of CSF pT217/
T217 3 CSF Ab 42/40 serves as a sensitive
biomarker for MAPT R406W mutation
carriers
We evaluated diagnostic values of CSF pT217/T217 and
CSF Ab 42/40 alone and in combination. CSF pT217/
T217 levels were increased in MAPT R406W mutation
carriers. However, the degree of increase was much
smaller compared to that of AD and we could not sepa-
rate MAPT R406W mutation carriers from the Control
or 4R tauopathy groups including PSP, CBS, sporadic
bvFTD, and FTD-MAPT P301L by CSF pT217/T217
alone (Fig. 2A, 2B, Fig. S6). Previous studies have indi-
cated an increase of CSF and plasma pT181 concentra-
tions in some cases of MAPT R406W mutation carriers,
but the increase was mild.50–52 These are consistent with
the insufficient sensitivity obtained from this study using
only CSF concentrations of pT181, pT217, or phospho-
rylation occupancies at T181 and T217 (pT181/T181 and
pT217/T217) as R406W biomarkers. Through quadrant
analysis, we demonstrated that both CSF pT217/T217
and CSF Ab 42/40 are necessary to distinguish MAPT
R406W mutation carriers with high accuracy. We also
demonstrated that a composite biomarker, CSF pT217/
T217 9 CSF Ab 42/40, contained sufficient sensitivity
and specificity to distinguish MAPT R406W mutation
carriers from the controls and 4R tauopathies (Fig. 2C,
Fig. S7C. AUC = 0.934, 0.960, respectively). This is com-
parable to the high specificity and sensitivity of CSF Ab
42/40 and CSF pT217/T217 to distinguish AD from the
controls (AUC = 0.926, 0.952, respectively). A combina-
tion of CSF Ab 42/40 and pT217/T217 ratios could be
used in future trials to select for presymptomatic MAPT
R406W mutation carriers and possibly other 3R+4R
tauopathies such as V337M. Moreover, longitudinal
measures of CSF pT217/T217 could reflect disease pro-
gression, suggesting that CSF Ab 42/40, CSF pT217/
T217, and composite biomarkers may serve as new sen-
sitive readouts in drug clinical trials against tauopathies
that can assess target engagement in MAPT R406W
mutation carriers.
CSF pT181/T181 may decrease in sporadic
bvFTD
Previous studies using immunoassays showed mixed
results in bvFTD, PSP, and CBS patients showing no or
mild changes in CSF total tau or pT181.16–18,53–57 Consis-
tent with multiple reports, our study did not show
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significant differences in CSF total tau or CSF pT181 con-
centrations alone between bvFTD, PSP, CBS, and Control
groups. However, by calculating the phosphorylation
occupancies within the same participant, we showed that
CSF pT181/T181 significantly decreases in sporadic
bvFTD. This may be achieved by normalizing the changes
in pT181 by T181, accounting for any physiological
increase in pT181 as total tau increases, and individual
variabilities such as age, sex, and genotype. Specificity and
sensitivity of CSF pT181/T181 biomarker in identifying
sporadic bvFTD from Controls or other tauopathies
(AUC <0.8) were not as high as a composite biomarker,
CSF pT217/T217 9 CSF Ab 42/40, in identifying MAPT
mutation carriers (AUC >0.9). This may be due to the
heterogeneity of the sporadic bvFTD cohort including
FTLD-tau, FTLD-TDP, and FTLD-FUS. Previous studies
showed that FTLD-TDP has lower CSF pT181/T181,58,59
which could be consistent with our results if the sporadic
bvFTD cohort included FTLD-TDP.
Limitations of this study and future
directions
The relatively small number of participants in some sub-
groups and the inclusion of pathologically unconfirmed
tauopathy and sporadic bvFTD cases may have decreased
diagnostic accuracies. MAPT V337M mutation carriers
may also be interesting to evaluate in the context of
3R+4R tauopathy. Future studies utilizing pathologically
confirmed cases, longitudinal samples with clinical and
PET assessments, and a larger cohort may facilitate addi-
tional analyses in ptau or tau that may be specific to
MAPT R406W mutation carriers, sporadic bvFTD, or
other subgroups of tauopathies.
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